Genmab A/S (NASDAQ:GMAB) Short Interest Up 8.7% in September

Genmab A/S (NASDAQ:GMAB) was the recipient of a large growth in short interest during the month of September. As of September 30th, there was short interest totalling 2,260,000 shares, a growth of 8.7% from the September 15th total of 2,080,000 shares. Based on an average daily trading volume, of 626,600 shares, the short-interest ratio is presently 3.6 days. Approximately 0.4% of the company’s stock are sold short.

Genmab A/S Price Performance

GMAB stock traded down $0.58 during midday trading on Wednesday, reaching $22.60. 1,330,715 shares of the company were exchanged, compared to its average volume of 612,399. Genmab A/S has a one year low of $22.52 and a one year high of $33.45. The firm has a market capitalization of $14.95 billion, a price-to-earnings ratio of 18.83, a price-to-earnings-growth ratio of 0.71 and a beta of 0.98. The business has a 50-day moving average price of $25.89 and a two-hundred day moving average price of $27.18.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Thursday, August 8th. The company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The company had revenue of $779.50 million for the quarter, compared to the consensus estimate of $734.60 million. As a group, analysts anticipate that Genmab A/S will post 1.27 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research note on Wednesday. Redburn Atlantic initiated coverage on Genmab A/S in a research note on Tuesday, October 8th. They issued a “buy” rating for the company. Morgan Stanley reiterated an “equal weight” rating and set a $31.00 price objective on shares of Genmab A/S in a research note on Wednesday, September 11th. Royal Bank of Canada raised shares of Genmab A/S from a “sector perform” rating to an “outperform” rating in a research note on Monday, July 15th. Finally, BTIG Research upped their price target on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $45.20.

Hedge Funds Weigh In On Genmab A/S

Institutional investors and hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. boosted its stake in Genmab A/S by 137.7% in the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock valued at $28,000 after purchasing an additional 544 shares during the period. GAMMA Investing LLC boosted its holdings in Genmab A/S by 194.0% in the 1st quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock valued at $34,000 after purchasing an additional 749 shares during the period. Allspring Global Investments Holdings LLC bought a new stake in Genmab A/S in the 1st quarter valued at about $43,000. Headlands Technologies LLC grew its position in shares of Genmab A/S by 1,702.8% during the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock worth $129,000 after purchasing an additional 4,853 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. increased its holdings in shares of Genmab A/S by 7.1% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock worth $182,000 after purchasing an additional 478 shares during the period. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.